<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697577</url>
  </required_header>
  <id_info>
    <org_study_id>2018-9567</org_study_id>
    <nct_id>NCT03697577</nct_id>
  </id_info>
  <brief_title>Pilot Study Assessing the Effect of Cyclin-dependent Kinase 4/6 Inhibitors on Body Composition in Patients With ER+/HER2- Metastatic Breast Cancer</brief_title>
  <official_title>Pilot Study Assessing the Effect of Cyclin-dependent Kinase 4/6 Inhibitors on Body Composition in Patients With ER+/HER2- Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate changes in body composition among patients who are
      treated with cyclin-dependent kinase (CDK) 4/6 inhibitors (abemaciclib, ribociclib, or
      palbociclib).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to evaluate changes in body composition among patients who are
      treated with cyclin-dependent kinase (CDK) 4/6 inhibitors (abemaciclib, ribociclib, or
      palbociclib). There is preliminary data suggesting that these drugs have more effect on body
      fat mass than body muscle mass. These drugs have already been approved by U.S Food and Drug
      Administration (FDA) to treat ER+/HER2- metastatic breast cancer. The investigators will
      follow up body composition changes among patients who receive CDK 4/6 inhibitors as part of
      their standard of care. Body composition changes will be measured from CT or PET/CT scans
      that are part of standard of care treatment, and from DEXA scans (as part of proposed study).
      The investigators will also conduct body measurements with measuring tape, and will draw
      blood tests to assess for fat biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total adipose tissue (TAT)</measure>
    <time_frame>24 months</time_frame>
    <description>Total Adipose tissue (TAT) is defined as the sum of intramuscular adipose tissue (IMAT), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT) obtained from L3 cross section from CT scans.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body fat mass (BFM)</measure>
    <time_frame>24 months</time_frame>
    <description>body fat mass will be obtained from dual-energy x-ray absorptiometry (DEXA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body lean mass(BLM)</measure>
    <time_frame>24 months</time_frame>
    <description>body lean mass(BLM) will be obtained from dual-energy x-ray absorptiometry (DEXA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle index (SMI)</measure>
    <time_frame>24 months</time_frame>
    <description>Skeletal muscle index (SMI) is defined as muscle area at L3 cross section from CT scans in cm2 divided by height in meters squared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose</measure>
    <time_frame>24 months</time_frame>
    <description>serum glucose will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist-to-hip ratio</measure>
    <time_frame>24 months</time_frame>
    <description>waist-to-hip ratio will be measured with measuring tape.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ER+/HER2- metastatic breast cancer</arm_group_label>
    <description>Subjects have metastatic ER+/HER2- breast cancer, and their doctor is offering treatment with CDK 4/6 inhibitors as standard of care treatment.We hypothesize that cyclin-dependent kinase (CDK) 4/6 inhibitors decrease fat mass among women with ER+/HER2- metastatic breast cancer without significant effect in the skeletal mass. Body composition will be obtained from CT scans (CT or PETCT) as part of their standard of care, and body fat mass will be obtained from DEXA scan(as part of proposed study)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CT scans</intervention_name>
    <description>Patients will undergo CT or PETCT as part of their standard of care</description>
    <arm_group_label>ER+/HER2- metastatic breast cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>DEXA scan</intervention_name>
    <description>Patients will undergo DEXA scan to measure body fat mass. This is part of proposed study.</description>
    <arm_group_label>ER+/HER2- metastatic breast cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Total Number of Specimens 60 Project/Storage Duration : 24 MONTHS Sample Type :BLOOD-SERUM
      Specimen Volume :15CC Sample Preservation Measures : STANDARD
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are being asked to participate in this study because they have metastatic
        ER+/HER2- breast cancer, and their doctor is offering treatment with CDK 4/6 inhibitors as
        standard of care treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the breast that is ER and/or PR positive,
             Her2 negative based on current ASCO-CAP guidelines

          -  Metastatic or locally advanced/inflammatory, unresectable breast cancer not amenable
             to potentially curative surgery.

          -  Measurable and/or non-measurable as defined by RECIST 1.1 criteria

          -  Patients must be a candidate to start an FDA approved CDK 4/6 inhibitor (palbociclib,
             ribociclib, abemaciclib) as part of standard of care treatment.

          -  Female, or male patients, and age &gt;18 years.

          -  ECOG performance status 0-2.

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  At least 30 days from major surgery before study enrollment, with full surgical wound
             healing and return to baseline performance status.

          -  Concomitant therapy with bisphosphonates, RANKL inhibitors or
             growth-colony-stimulating factor (G-CSF) is allowed as per physician decision.

        Exclusion Criteria:

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to CDK 4/6 inhibitors or other agents used in the study (e.g.,
             fulvestrant, letrozole, anastrozole, exemestane).

          -  BMI &lt; 18.5

          -  Prior CDK 4/6 use in any setting.

          -  Inability to undergo anthropometric measurements.

          -  Inability to undergo CT scan imaging.

          -  Recent radiation or chemotherapy within 4 weeks

          -  Women of child-bearing potential must not be pregnant or breast feeding. They must
             also agree to use adequate contraception (hormonal or barrier method of birth control)
             and not be breast feeding prior to study entry, for the duration of study
             participation, and for up to 10 days after completion of all protocol therapy. Should
             a woman become pregnant or suspect she is pregnant while participating in this study
             or up to 10 days after completion of protocol therapy, she should inform her treating
             physician immediately.

          -  Intercurrent illness that would substantially increase the risk of treatment
             associated complications (e.g., active infection, uncontrolled diabetes mellitus or
             hypertension)

          -  Psychiatric illness/social situations that would interfere with the patient's ability
             to comply with the treatment regimen.

          -  Patients with untreated brain metastasis are excluded. Patients with a prior history
             of brain metastasis are eligible if they have received prior brain radiation (whole
             brain or stereotatactic radiosurgery) or surgery, have stable intracranial disease for
             at least 3 months after completion of local therapy, and are not taking
             corticosteroids for treatment of brain metastasis.

          -  Treatment with bevacizumab, other targeted therapies, or other investigational agents
             within the past 4 weeks.

          -  Patients who have not recovered (i.e., CTCAE Grade â‰¤1 or baseline) from an adverse
             event due to a previously administered agent, excluding alopecia.

          -  Patients with inability to swallow and retain pills

          -  Malabsorption syndrome or other gastrointestinal illness that could affect oral
             absorption.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesus Anampa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jesus Anampa, MD</last_name>
    <phone>718-405-8505</phone>
    <email>janampa@montefiore.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Fehn, RN</last_name>
    <phone>718-405-8404</phone>
    <email>kfehn@montefiore.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus D Anampa, MD,MS</last_name>
      <phone>718-405-8505</phone>
      <email>janampa@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Karen Fehn, RN</last_name>
      <phone>7184058505</phone>
      <email>kfehn@montefiore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jesus Anampa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Sparano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 2, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Jesus Anampa Mesias</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>cyclin-dependent kinase (CDK) 4/6 inhibitors</keyword>
  <keyword>Body composition</keyword>
  <keyword>body fat mass</keyword>
  <keyword>metastatic ER+/HER2- breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

